MA49888A - Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1 - Google Patents

Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1

Info

Publication number
MA49888A
MA49888A MA049888A MA49888A MA49888A MA 49888 A MA49888 A MA 49888A MA 049888 A MA049888 A MA 049888A MA 49888 A MA49888 A MA 49888A MA 49888 A MA49888 A MA 49888A
Authority
MA
Morocco
Prior art keywords
compounds used
macrocyclic compounds
ros1 inhibitors
kinase
kinase ros1
Prior art date
Application number
MA049888A
Other languages
English (en)
Inventor
Steven W Andrews
James F Blake
Julia Haas
Gabrielle R Lolakowski
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MA49888A publication Critical patent/MA49888A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA049888A 2017-03-16 2018-03-16 Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1 MA49888A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762472185P 2017-03-16 2017-03-16

Publications (1)

Publication Number Publication Date
MA49888A true MA49888A (fr) 2020-06-24

Family

ID=61913541

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049888A MA49888A (fr) 2017-03-16 2018-03-16 Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1

Country Status (19)

Country Link
US (3) US10688100B2 (fr)
EP (1) EP3595651A1 (fr)
JP (1) JP2020514356A (fr)
KR (1) KR20190126003A (fr)
CN (1) CN110769820A (fr)
AU (1) AU2018234726A1 (fr)
BR (1) BR112019019101A2 (fr)
CA (1) CA3056754A1 (fr)
CL (1) CL2019002612A1 (fr)
IL (1) IL269216A (fr)
JO (1) JOP20190213A1 (fr)
MA (1) MA49888A (fr)
MX (1) MX2019010988A (fr)
PH (1) PH12019502069A1 (fr)
RU (1) RU2019132666A (fr)
SG (1) SG11201908532UA (fr)
TN (1) TN2019000263A1 (fr)
TW (1) TW201838631A (fr)
WO (1) WO2018170381A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2350075T3 (da) 2008-09-22 2014-05-26 Array Biopharma Inc Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
PT3106463T (pt) 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
EP3218380B1 (fr) 2014-11-16 2021-03-17 Array Biopharma, Inc. Préparation d'une forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
IL304018A (en) 2016-04-04 2023-08-01 Loxo Oncology Inc Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2952056T3 (es) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CA3081790C (fr) * 2017-11-10 2023-03-07 Angex Pharmaceutical, Inc. Composes macrocycliques en tant qu'inhibiteurs de kinase trk et leurs utilisations
MX2020004991A (es) 2017-11-17 2022-02-10 Univ Illinois Terapia oncológica mediante la degradación de la señalización dual de mek.
US12090153B2 (en) 2018-10-05 2024-09-17 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
DK3870579T3 (da) 2018-10-22 2025-01-02 Alumis Inc Tyk2-inhibitorer og anvendelser deraf
JP7586829B2 (ja) * 2019-03-11 2024-11-19 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN113874021B (zh) * 2019-03-26 2024-07-09 温缇克斯生物科学公司 Tyk2假激酶配体
CA3154837A1 (fr) * 2019-10-16 2021-04-22 Sebastiano BATTAGLIA Multitherapie pour le traitement de cancers
AU2020378345A1 (en) 2019-11-08 2022-06-02 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
CA3159348A1 (fr) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methodes pour le traitement de cancers qui ont acquis une resistance aux inhibiteurs de kinase
JP7374532B2 (ja) * 2019-11-18 2023-11-07 クワンチョウ ジョーヨー ファーマテック カンパニー，リミティド 選択性の高いｒｏｓ１阻害剤としての化合物、及びその使用
CN112812128B (zh) * 2019-11-18 2024-04-02 正大天晴药业集团股份有限公司 作为alk和ros调节剂的大环化合物
CN113004305B (zh) * 2019-12-19 2024-04-09 赛诺哈勃药业（成都）有限公司 大环化合物及其制备方法和用途
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
KR20230037564A (ko) * 2020-07-10 2023-03-16 블로썸힐 테라퓨틱스, 인크. 거대고리 화합물 및 그의 용도
WO2022182845A1 (fr) * 2021-02-25 2022-09-01 Blossomhill Therapeutics, Inc. Macrocycles et leur utilisation
CN113072564A (zh) * 2021-03-23 2021-07-06 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其用途

Family Cites Families (390)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017286A (en) 1909-03-01 1912-02-13 Du Pont Powder Co Apparatus for treating explosive powder.
US1013712A (en) 1911-06-03 1912-01-02 Alfred D Williams Tie and rail-fastener.
EP0009517A1 (fr) 1978-10-04 1980-04-16 THE PROCTER & GAMBLE COMPANY Contraceptif intravaginal
NZ234143A (en) 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
RU2139281C1 (ru) 1993-11-30 1999-10-10 Джи Ди Сирл энд Компани Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5430021A (en) 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
CN1163509C (zh) 1996-05-08 2004-08-25 拜奥根有限公司 刺激神经和肾生长的RET配体(RetL)
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
CA2206201A1 (fr) 1996-05-29 1997-11-29 Yoshiaki Isobe Derives du pyrazole et leur emploi en pharmacie
US6682921B1 (en) 1996-08-21 2004-01-27 New York University Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
JP3898296B2 (ja) 1996-08-28 2007-03-28 ポーラ化成工業株式会社 ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬
AU7079998A (en) 1997-04-25 1998-11-24 Takeda Chemical Industries Ltd. Condensed pyridazine derivatives, their production and use
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
WO2001016169A2 (fr) 1999-09-01 2001-03-08 Biogen, Inc. COMPOSITIONS A BASE DE LIGAND 5 (RetL5) ET SES UTILISATIONS
US6534085B1 (en) 1999-09-23 2003-03-18 Bioresponse L.L.C. Phytochemicals for promoting weight loss
DE60134067D1 (de) * 2000-01-24 2008-07-03 Graniterie Petitjean S A S Zwischenplatte zum Einsetzen in einem Schneidschlitz
FI20000403A0 (fi) 2000-02-22 2000-02-22 Hannu Sariola GDNF perhesukuisten yhdisteiden käyttö kivessyövän hoitoon tarkoitettujen tuotteiden valmistamiseksi
KR100823764B1 (ko) 2000-06-22 2008-04-21 제넨테크, 인크. 아고니스트 안티-티알케이-씨 모노클로날 항체
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
CA2975521A1 (fr) 2001-05-30 2002-12-05 Genentech, Inc. Anticorps anti-ngf pour le traitement de divers troubles
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
US7449488B2 (en) 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
ITMI20021620A1 (it) 2002-07-23 2004-01-23 Novuspharma Spa Composto ad ativita' antitumorale
US20060116381A1 (en) 2002-07-24 2006-06-01 Fagin James A 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-ben-zamide for treating mutated-ret kinase associated diseases
JP4024624B2 (ja) 2002-08-26 2007-12-19 富士通株式会社 半導体装置の製造方法及び製造装置
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1537116B1 (fr) 2002-09-04 2010-06-02 Schering Corporation Pyrazolopyrimidines utilisable pour le traitement des maladies cancereuses
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004052315A2 (fr) 2002-12-11 2004-06-24 Merck & Co., Inc. Inhibiteurs des tyrosine kinases
WO2004052286A2 (fr) 2002-12-11 2004-06-24 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
US7514446B2 (en) 2003-02-20 2009-04-07 Smithkline Beecham Corporation Pyrimidine compounds
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US20070037150A1 (en) 2003-02-21 2007-02-15 The Johns Hopkins University Tyrosine kinome
JP2004277337A (ja) 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
EP1608652A1 (fr) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Composes pyrazolopyrimidines et leur utilisation en medecine
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
WO2004089471A2 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Utilisation pharmaceutique de pyrazolo[1,5-a]pyrimidines substituees
WO2004089415A2 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Therapie combinatoire utilisant un inhibiteur de 11$g(b)-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides pour minimiser les effets secondaires associes a la therapie a base d'agoniste du recepteur de glucocorticoides
KR20060011977A (ko) 2003-04-28 2006-02-06 가르파마 컴퍼니 리미티드 갈렉틴 9 유도 인자
PA8603801A1 (es) 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EA009517B1 (ru) 2003-06-27 2008-02-28 Байер Кропсайенс Аг Пиразолопиримидины
CN1849138B (zh) 2003-07-15 2011-11-30 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US20090143399A1 (en) 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2005044835A1 (fr) 2003-10-27 2005-05-19 Genelabs Technologies, Inc. Procedes de preparation de derives 7-(2'-$g(b)-d-ribofuranosyl substitue)-4-(nr2r3)-5-(ethyn-1-yl substitue)-pyrrolo[2,3-d]pyrimidine
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
WO2005051366A2 (fr) 2003-11-28 2005-06-09 Novartis Ag Derives de diaryluree utilises en traitement de maladies dependant de proteines kinases
EP1697384B1 (fr) 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Derives de pyrido- et pyrimidopyrimidine comme agents anti-proliferation
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
WO2005068424A1 (fr) 2004-01-20 2005-07-28 Cell Therapeutics Europe S.R.L. Derives d'indolinone en tant qu'inhibiteurs de tyrosine kinase de recepteurs
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
WO2005099363A2 (fr) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methodes de diagnostic, de prevention et de traitement de metastases cancereuses
CN1938311A (zh) 2004-03-30 2007-03-28 因特蒙公司 作为病毒复制抑制剂的大环化合物
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1797054A2 (fr) 2004-08-02 2007-06-20 OSI Pharmaceuticals, Inc. Composes a base de pyrrolopyrimidine a substitution arylamine inhibiteurs de kinases multiples
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
WO2006050076A1 (fr) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Composes de pyrrolyle fusionnes substitues par pyrimidinyle et utiles dans le traitement des troubles induits par la kinase
EP1812440B1 (fr) 2004-11-04 2010-09-22 Vertex Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidines utiles en tant qu'inhibiteurs de proteines kinases
JO3088B1 (ar) 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
CN101119996A (zh) 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
EP1853602B1 (fr) 2005-02-16 2010-07-14 AstraZeneca AB Composés chimiques
WO2006089298A2 (fr) 2005-02-18 2006-08-24 Attenuon, Llc Derives de diazepine fusionnes pyrimidine et pteridines fusionnees indole
PL1869049T3 (pl) 2005-03-21 2009-07-31 Lilly Co Eli Związki imidazopirydazyny
GB0507575D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US7402579B2 (en) 2005-04-15 2008-07-22 Cylene Pharmaceuticals, Inc. Quinobenzoxazine analogs and compositions
CN101208093A (zh) 2005-04-27 2008-06-25 阿斯利康(瑞典)有限公司 吡唑-嘧啶衍生物在治疗疼痛中的用途
BRPI0610184A2 (pt) 2005-05-16 2012-09-25 Astrazeneca Ab composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica
WO2006128042A2 (fr) 2005-05-26 2006-11-30 The Johns Hopkins University Procedes d'identification de mutations dans un acide nucleique
CN101233129A (zh) 2005-05-31 2008-07-30 普法尔家族联合企业（1996.7.9） 取代的联芳杂环衍生物作为蛋白激酶抑制剂治疗癌症及其他疾病
WO2006130673A1 (fr) 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines utilisees pour traiter des troubles dont la mediation est assuree par des kinases
CN100406650C (zh) 2005-06-05 2008-07-30 徐斌 一种抗特大变位的模块式梳型桥梁伸缩缝装置
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
PL2395004T3 (pl) 2005-06-22 2016-08-31 Plexxikon Inc Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej
US20070025540A1 (en) 2005-07-07 2007-02-01 Roger Travis Call center routing based on talkativeness
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
KR101294467B1 (ko) 2005-07-25 2013-09-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 거대고리형 억제제
EP1910369A1 (fr) 2005-07-29 2008-04-16 Astellas Pharma Inc. Hétérocycles fusionnés en tant qu inhibiteurs de lck
WO2007019058A1 (fr) 2005-08-03 2007-02-15 Eastman Chemical Company Poudre de succinate de tocopheryl polyethylene glycol et procede de preparation de celle-ci
AU2006283592A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
RS53195B2 (sr) 2005-08-25 2018-08-31 Creabilis Therapeutics Spa Polimerni konjugati k-252a i njihovi derivati
WO2007025090A2 (fr) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibiteurs de kinase mapk/erk
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AR057979A1 (es) 2005-10-06 2008-01-09 Schering Corp PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
CN101360499B (zh) 2005-10-06 2015-10-07 默沙东公司 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途
WO2007057782A2 (fr) 2005-10-11 2007-05-24 Centre National De La Recherche Scientifique (Cnrs) Composes et trousses pour la detection et la quantification de l'apoptose cellulaire
BRPI0617274A2 (pt) 2005-10-11 2011-07-19 Intermune Inc compostos e métodos para a inibição de replicação viral de hepatite c
JP5119157B2 (ja) 2005-10-21 2013-01-16 エクセリクシス， インク． カゼインキナーゼｉｉ（ｃｋ２）モジュレーターとしてのピラゾロ−ピリミジン類
JP2009519218A (ja) 2005-11-03 2009-05-14 エスジーエックス ファーマシューティカルズ、インコーポレイテッド ピリミジニル−チオフェンキナーゼモジュレータ
EP1785420A1 (fr) 2005-11-14 2007-05-16 4Sc Ag Analogues de thiazole et leurs utilisation
US20070149523A1 (en) 2005-11-14 2007-06-28 Jan Ehlert Thiazole Analogues and Uses Thereof
WO2007057397A1 (fr) 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Traitement du cancer
WO2007057399A2 (fr) 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Traitement du cancer
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
AU2006322187A1 (en) 2005-12-08 2007-06-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
WO2007077435A1 (fr) 2005-12-30 2007-07-12 Astex Therapeutics Limited Composes pharmaceutiques
WO2007084815A2 (fr) 2006-01-19 2007-07-26 Janssen Pharmaceutica, N.V. Inhibiteurs de la thienopyrimidine kinase substituee
WO2007087245A2 (fr) 2006-01-24 2007-08-02 Merck & Co., Inc. Inhibition de la tyrosine kinase ret
JP5256047B2 (ja) 2006-01-27 2013-08-07 シャンハイ ヘンルイ ファーマシューティカル カンパニー リミテッド ピロロ［３，２−ｃ］ピリジン−４−オン２−インドリノン（ｉｎｄｏｌｉｎｏｎｅ）プロテインキナーゼ阻害剤
WO2007102679A1 (fr) 2006-03-06 2007-09-13 Je Il Pharmaceutical Co., Ltd. Nouveaux dérivés de la thiénopyrimidine ou leurs sels pharmacocompatibles, leur procédé de préparation, et préparations pharmaceutiques les comprenant
CA2645137A1 (fr) 2006-03-07 2007-09-13 James F. Blake Derives heterobicycliques de pyrazole et methodes d'utilisation
CN101563336A (zh) 2006-03-16 2009-10-21 诺瓦提斯公司 用于治疗特别是黑素瘤的杂环有机化合物
KR101549364B1 (ko) 2006-03-17 2015-09-01 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
KR20090008286A (ko) 2006-03-27 2009-01-21 네르비아노 메디칼 사이언시스 에스.알.엘. 키나제 억제제로서의 피리딜- 및 피리미디닐-치환된 피롤-,티오펜- 및 푸란- 유도체
GB0606805D0 (en) 2006-04-04 2006-05-17 Novartis Ag Organic compounds
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
MX2008014618A (es) 2006-05-15 2008-11-28 Irm Llc Composiciones y metodos para inhibidores de cinasas del receptor fgf.
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
EP1873157A1 (fr) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines et sels de ceux-ci, compositions pharmaceutiques contenant ces composes, procedes de preparation associes, et leur utilisation
TW201345908A (zh) 2006-07-05 2013-11-16 Mitsubishi Tanabe Pharma Corp 吡唑并〔１，５-ａ〕嘧啶化合物
EP2058309A4 (fr) 2006-08-04 2010-12-22 Takeda Pharmaceutical Composé hétérocyclique à cycles fusionnés
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CA2663091A1 (fr) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulateurs de la kinase associee au recepteur de l'interleukine-1
US20110195072A1 (en) 2006-09-12 2011-08-11 Anne Boulay Non-neuroendocrine cancer therapy
KR101507375B1 (ko) 2006-09-15 2015-04-07 엑스커버리 홀딩 컴퍼니 엘엘씨 키나아제 억제제 화합물
RU2009115954A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
US20120225057A1 (en) 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
EP1918291A1 (fr) 2006-10-30 2008-05-07 Novartis AG Dérives de pyrazole fusionnes substitués de 3-aminocarbonyle comme modulateurs de protéine kinase
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
WO2008058126A2 (fr) 2006-11-06 2008-05-15 Supergen, Inc. Dérivés d'imidazo[1,2-b]pyridazine et de pyrazolo[1,5-a]pyrimidine et utilisation de ceux-ci comme inhibiteurs de protéines kinases
EP2099774A4 (fr) 2006-11-15 2010-11-24 Ym Biosciences Australia Pty L Inhibiteurs de l'activité kinase
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
US7872018B2 (en) 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US8741849B2 (en) 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
US20080199426A1 (en) 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
CA2675979A1 (fr) 2007-01-19 2008-07-24 Bayer Healthcare Llc Traitement de cancers presentant une resistance a des agents chimiotherapeutiques
US20080234267A1 (en) 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
CN101801972A (zh) 2007-03-28 2010-08-11 英诺瓦西亚公司 作为硬脂酰-辅酶a去饱和酶抑制剂的吡唑并[1,5-a]嘧啶
WO2008124323A1 (fr) 2007-04-03 2008-10-16 Array Biopharma Inc. Composés imidazo[1,2-a]pyridine utilisés comme inhibiteurs des récepteurs à activité tyrosine kinase
US20110189167A1 (en) 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
EA019524B1 (ru) 2007-05-04 2014-04-30 Айрм Ллк СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ с-kit И PDGFR
WO2008138184A1 (fr) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
CA2687909C (fr) 2007-06-21 2015-09-15 Janssen Pharmaceutica Nv Indolin-2-ones et aza-indolin-2-ones
US20090012045A1 (en) 2007-06-26 2009-01-08 Rigel Pharmaceuticals, Inc. Methods of Treating Cell Proliferative Disorders
CN101801962A (zh) 2007-07-09 2010-08-11 阿斯利康(瑞典)有限公司 用于治疗增殖疾病的三取代嘧啶衍生物
US20100209488A1 (en) 2007-07-16 2010-08-19 The Regents Of The University Of California Protein kinase modulating compounds and methods for making and using them
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
US8293747B2 (en) 2007-07-19 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
EA018503B1 (ru) 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
WO2009017838A2 (fr) 2007-08-01 2009-02-05 Exelixis, Inc. Combinaisons d'inhibiteurs jak-2 et d'autres agents
KR101709488B1 (ko) 2007-08-10 2017-02-24 리제너론 파아마슈티컬스, 인크. 인간 신경성장인자에 대한 고친화성 인간 항체
EP2025678A1 (fr) 2007-08-17 2009-02-18 Oncalis AG Composés pyrazolo[3,4-d]pyrimidine et leur utilisation comme modulateur de protein kinase
WO2009042646A1 (fr) 2007-09-24 2009-04-02 Curis, Inc. Agents antiprolifératifs
CN101883774A (zh) 2007-10-16 2010-11-10 惠氏有限责任公司 噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途
EA201000603A1 (ru) 2007-10-23 2010-12-30 Новартис Аг ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
WO2009060197A1 (fr) 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines utilisées comme qu'inhibiteurs de protéine kinases
WO2009070567A1 (fr) 2007-11-28 2009-06-04 Schering Corporation 2-fluoropyrazolo[1,5-a] pyrimidines en tant qu'inhibiteurs de protéine kinase
JP5400791B2 (ja) 2007-12-04 2014-01-29 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ジヒドロプテリジン−６−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
CN102015769B (zh) 2008-01-17 2014-12-10 Irm责任有限公司 改进的抗-trkb抗体
JP2009203226A (ja) 2008-01-31 2009-09-10 Eisai R & D Management Co Ltd ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤
TW200938542A (en) 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
WO2009103076A1 (fr) 2008-02-15 2009-08-20 Oxigene, Inc. Méthodes et compositions pour améliorer l'efficacité des inhibiteurs des récepteurs tyrosine kinases (rtk)
WO2009117097A1 (fr) 2008-03-19 2009-09-24 Chembridge Corporation Nouveaux inhibiteurs de tyrosine kinase
US8207165B2 (en) 2008-03-28 2012-06-26 Nerviano Medical Sciences S.R.L. 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EA019507B1 (ru) 2008-05-13 2014-04-30 Айрм Ллк Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MY155535A (en) 2008-05-23 2015-10-30 Novartis Ag Derivatives of quinolines and quinoxalines as protien tyrosine kinase inhibitors
AU2009257635A1 (en) 2008-06-10 2009-12-17 Plexxikon, Inc. 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
WO2009155527A2 (fr) 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Inhibiteurs de phosphatidylinositol 3 kinase
CA2730190A1 (fr) 2008-07-14 2010-01-21 Queen's University At Kingston Compositions pharmaceutiques contenant des inhibiteurs de ret et procedes de traitement du cancer
ES2532732T3 (es) 2008-07-29 2015-03-31 Nerviano Medical Sciences S.R.L. Uso de un inhibidor de CDK para el tratamiento del glioma
US20100075916A1 (en) 2008-09-05 2010-03-25 Auspex Pharmaceuticals, Inc. Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases
EP2161271A1 (fr) 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Inhibiteurs d'alpha-carboline de NMP-ALK, RET, et Bcr-Abl
EP2376492B1 (fr) 2008-09-19 2015-04-08 Nerviano Medical Sciences S.r.l. Dérivés de 3,4-dihydro-2h-pyrrolo[1,2-a]pyrazine-1-one
DK2350075T3 (da) 2008-09-22 2014-05-26 Array Biopharma Inc Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
ES2435918T3 (es) 2008-09-26 2013-12-26 National Health Research Institutes Compuestos multicíclicos condensados como inhibidores de las proteína-cinasas
PT3106463T (pt) 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
RU2539568C2 (ru) 2008-10-31 2015-01-20 Дженентек, Инк. Пиразолопиримидиновые соединения-ингибиторы jak и способы
EP2358725A1 (fr) 2008-11-06 2011-08-24 Ambit Biosciences Corporation Composés imidazolothiazoles utilisés comme modulateurs de protéine kinases
CN102223885B (zh) 2008-11-24 2013-04-03 内尔维阿诺医学科学有限公司 用于治疗间皮瘤的cdk抑制剂
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
DK2881402T3 (en) 2009-02-12 2017-08-28 Cell Signaling Technology Inc Mutant ROS expression in human liver cancer
WO2010111527A1 (fr) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines en tant qu'inhibiteurs de la kinase et leur utilisation médicale
TWI410418B (zh) 2009-04-29 2013-10-01 Ind Tech Res Inst 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
CA2760061C (fr) 2009-05-08 2017-02-28 Astellas Pharma Inc. Compose de carboxamide heterocyclique diamino
WO2010144909A1 (fr) 2009-06-12 2010-12-16 Novartis Ag Composés hétérocycliques fondus et leurs utilisations
JP5789602B2 (ja) 2009-06-15 2015-10-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ピリミジニルピロロピリジノン誘導体、これらの製造のための方法およびキナーゼ阻害剤としてのこれらの使用
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
KR101147550B1 (ko) 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
KR101116756B1 (ko) 2009-10-27 2012-03-13 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 신규의 1,6-치환된 인돌 화합물
ES2658290T3 (es) 2009-10-29 2018-03-09 Genosco Inhibidores de cinasa
JP5740409B2 (ja) 2009-11-13 2015-06-24 ジェノスコ キナーゼ阻害剤
KR101094446B1 (ko) 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
JP5883395B2 (ja) 2010-01-29 2016-03-15 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ タンパク質キナーゼモジュレーターとしての６，７−ジヒドロイミダゾ［１，５−ａ］ピラジン−８（５ｈ）−オン誘導体
CA2786438C (fr) 2010-01-29 2015-10-13 Hanmi Science Co., Ltd. Derives thieno[3,2-d]pyrimidines avec activite inhibitrice sur proteines kinases
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
EP2536414B1 (fr) 2010-02-18 2016-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour la prévention de métastases cancéreuses
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
JP6121903B2 (ja) 2010-08-19 2017-04-26 ゾエティス・ベルジャム・エス・アー 抗ｎｇｆ抗体およびその使用
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
WO2012037155A2 (fr) 2010-09-13 2012-03-22 Gtx, Inc. Inhibiteurs des tyrosines kinases
WO2012047017A2 (fr) 2010-10-05 2012-04-12 크리스탈지노믹스(주) Dérivé 2,3-dihydro-isoindol-1-one et composition le comprenant
JP2014005206A (ja) 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
KR20190112175A (ko) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
US8618146B2 (en) 2011-01-03 2013-12-31 Dr. Reddy's Laboratories Limited Epothilone compound formulations
EP2668188B1 (fr) 2011-01-26 2016-05-18 Nerviano Medical Sciences S.r.l. Dérivés tricycliques, leur procédé de préparation et leur utilisation à titre d'inhibiteurs de kinases
CN103339134B (zh) 2011-01-26 2015-12-23 内尔维阿诺医学科学有限公司 三环吡咯并衍生物、它们的制备方法和它们作为激酶抑制剂的应用
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
PL2672967T3 (pl) 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu
CN103403002B (zh) 2011-02-24 2016-06-22 内尔维阿诺医学科学有限公司 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物
KR20140014184A (ko) 2011-02-25 2014-02-05 아이알엠 엘엘씨 Trk 억제제로서의 화합물 및 조성물
WO2012135631A1 (fr) 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc 5-(pyrazin-2-yl)-1h-pyrazolo[3,4-b]pyridine substituée et dérivés de pyrazolo[3,4-b]pyridine en tant qu'inhibiteurs de protéine kinase
ES2759615T3 (es) 2011-04-01 2020-05-11 Univ Utah Res Found Análogos de N-fenilpirimidina-2-amina sustituidos como inhibidores de la quinasa AXL
EP2702055A1 (fr) 2011-04-11 2014-03-05 Nerviano Medical Sciences S.r.l. Dérivés pyrazolyl-pyrimidine en tant qu'inhibiteurs des kinases
RU2621732C2 (ru) 2011-04-19 2017-06-07 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные пиримидинилпирролы, активные в качестве ингибиторов киназы
DK2707359T3 (en) 2011-05-12 2017-01-23 Nerviano Medical Sciences Srl SUBSTITUTED INDAZOLD DERIVATIVES ACTIVE AS KINase INHIBITORS
MY173181A (en) 2011-05-13 2020-01-02 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
RU2477723C2 (ru) 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
EP2736514B1 (fr) 2011-07-28 2017-10-18 Nerviano Medical Sciences S.r.l. Pyrimidinyl-pyrroles substitués alcynyle agissant comme inhibiteurs de kinase
WO2013016720A2 (fr) 2011-07-28 2013-01-31 Gerinda Therapeutics, Inc. Nouveaux dérivés biaryl-hétérocycliques substitués en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer et d'autres maladies
US9216172B2 (en) 2011-08-04 2015-12-22 National Cancer Center Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene
WO2013028817A1 (fr) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Molécules de fusion kif5b-ret inédites et leurs utilisations
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
WO2013036232A2 (fr) 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Méthodes et compositions pouvant être utilisées en vue du traitement de maladies myéloprolifératives et d'autres maladies prolifératives
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
WO2013042137A1 (fr) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Hétérocycles bicycliques convenant comme inhibiteurs de l'irak4
WO2013050448A1 (fr) 2011-10-07 2013-04-11 Nerviano Medical Sciences S.R.L. Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitué par 4-alkyle en tant qu'inhibiteurs de kinases
US9145418B2 (en) 2011-10-07 2015-09-29 Nerviano Medical Sciences S.R.L. Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
WO2013059740A1 (fr) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Nouvelles molécules de fusion alk et ntrk1 et leurs utilisations
EP2779833A4 (fr) 2011-11-14 2015-03-18 Tesaro Inc Modulation de certaines tyrosine kinases
CN104080907A (zh) 2011-11-30 2014-10-01 日本国立癌症研究中心 诱导恶性干细胞
WO2013088257A1 (fr) 2011-12-12 2013-06-20 Dr. Reddy's Laboratories Ltd. Composés hétérocycliques substitués en tant qu'inhibiteurs du récepteur kinase a lié à la tropomyosine (trka)
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
RS59420B1 (sr) 2011-12-30 2019-11-29 Hanmi Pharmaceutical Co Ltd Derivati tieno[3,2-d]pirimidina sa inhibitornom aktivnošću za proteinske kinaze
JP2015109806A (ja) 2012-03-22 2015-06-18 アステラス製薬株式会社 新規ｒｅｔ融合体の検出法
EP2842955B1 (fr) 2012-04-26 2016-10-05 ONO Pharmaceutical Co., Ltd. Composé inhibiteur de trk
JP2013226108A (ja) 2012-04-27 2013-11-07 Astellas Pharma Inc 新規ｎｔｒｋ２活性化変異の検出法
JP2015516439A (ja) 2012-05-10 2015-06-11 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０阻害化合物で癌を治療すること
JP6231556B2 (ja) 2012-05-23 2017-11-15 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｎ−［５−（３，５−ジフルオロ−ベンジル）−１ｈ−インダゾール−３−イル］−４−（４−メチル−ピペラジン−１−イル）−２−（テトラヒドロ−ピラン−４−イルアミノ）−ベンズアミドの調製方法
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
DK2872491T3 (da) 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
CN104619841A (zh) 2012-07-26 2015-05-13 日本国立癌症研究中心 Cep55基因与ret基因的融合基因
EP2689778A1 (fr) 2012-07-27 2014-01-29 Pierre Fabre Medicament Dérivés de type azaindazole ou diazaindazole pour le traitement de la douleur
WO2014019908A2 (fr) 2012-08-02 2014-02-06 Nerviano Medical Sciences S.R.L. Pyrroles substitués actifs en tant qu'inhibiteurs de kinase
US20150218652A1 (en) 2012-08-31 2015-08-06 The Regents Of The Unversity Of Colorado, A Body Corporate Methods for diagnosis and treatment of cancer
WO2014039971A1 (fr) 2012-09-07 2014-03-13 Exelixis, Inc. Inhibiteurs de met, vegfr et ret pour l'utilisation dans le traitement d'un adénocarcinome du poumon
US20140084039A1 (en) 2012-09-24 2014-03-27 Electro Scientific Industries, Inc. Method and apparatus for separating workpieces
TR201815994T4 (tr) 2012-09-25 2018-11-21 Chugai Pharmaceutical Co Ltd Ret inhibitörü.
JP2014082984A (ja) 2012-10-23 2014-05-12 Astellas Pharma Inc 新規ｎｔｒｋ２活性化変異の検出法
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
HK1214831A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型融合分子及其应用
US9604980B2 (en) 2012-11-07 2017-03-28 Nerviano Medical Sciences S.R.L. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
EA029706B1 (ru) 2012-11-12 2018-05-31 Игнайта, Инк. Сложные алкиловые эфиры бендамустина и способы их применения
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078331A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-(arylalkyle)-n'-pyrazolyle-urée, de thiourée, de guanidine et de cyanoguanidine en tant qu'inhibiteurs de la kinase trka
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078325A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-aryle monocycliques, n'-pyrazolyl-urée, thiourée, guanidine et cyanoguanidine utiles comme inhibiteurs de trka kinase
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078328A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-pyrrolidinyle, n'-pyrazolyl-urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
WO2014078378A1 (fr) 2012-11-13 2014-05-22 Array Biopharma Inc. Composés de n-pyrrolidinyle urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
EP2920166B1 (fr) 2012-11-13 2016-11-02 Array Biopharma, Inc. Composes bicycliques a base d' uree, thiouree, guanidine ou cyanoguanidine utiles dans le traitement de la douleur
EP2922844B1 (fr) 2012-11-13 2018-01-10 Array Biopharma, Inc. Composés de n-pyrrolidinyle, n'-pyrazolyl-urée, thio-urée,guanidine et cyanoguanidine en tant qu'inhibiteurs de la kinase trka
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
BR112015002626A2 (pt) 2012-11-29 2017-09-26 Yeda Res & Dev métodos para prevenção de metástases tumorais, tratamento e prognostico do câncer e identificação dos agentes que são inibidores da metástase putativa
WO2014086284A1 (fr) 2012-12-04 2014-06-12 上海医药集团股份有限公司 Composé de 3-cyanoquinoléine deutéré, composition pharmaceutique le comprenant, leur procédé de préparation et leur utilisation
US9447135B2 (en) 2012-12-14 2016-09-20 University Of Kentucky Research Foundation Semi-synthetic mithramycin derivatives with anti-cancer activity
CN104995184B (zh) 2012-12-28 2018-01-02 晶体基因技术株式会社 作为btk激酶抑制剂的2,3‑二氢异吲哚‑1‑酮诱导体与含此类的药学组合物
FR3000494B1 (fr) 2012-12-28 2015-08-21 Oribase Pharma Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases
FR3000492B1 (fr) 2012-12-28 2015-09-11 Oribase Pharma Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
FR3000493A1 (fr) 2012-12-28 2014-07-04 Oribase Pharma Nouveaux inhibiteurs de proteines kinases
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
HUE042591T2 (hu) 2013-02-19 2019-07-29 Ono Pharmaceutical Co TRK-gátló vegyület
EP2981613A4 (fr) 2013-02-22 2016-11-02 Boris C Bastian Polynucléotides de fusion et polypeptides de fusion associés au cancer, en particulier au mélanome, et leurs utilisations en tant que cibles thérapeutiques et diagnostiques
US20140243332A1 (en) * 2013-02-27 2014-08-28 Oregon Health & Science University Methods of treating cancers characterized by aberrent ros1 activity
AU2014229233B2 (en) 2013-03-15 2016-08-11 Glaxosmithkline Intellectual Property Development Limited Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors
WO2014160521A1 (fr) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Dérivés de pipérazine et leur utilisation comme modulateurs de kit
EP3795696B1 (fr) 2013-03-15 2023-04-26 The Board of Trustees of the Leland Stanford Junior University Identification et utilisation de marqueurs tumoraux d'acides nucléiques circulants
JP2016515508A (ja) 2013-03-15 2016-05-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 融合タンパク質及びその方法
WO2014152777A2 (fr) 2013-03-15 2014-09-25 Insight Genetics, Inc. Procédés et compositions pour le diagnostic et le traitement de cancers résistants aux inhibiteurs de ros1
US9850543B2 (en) 2013-03-15 2017-12-26 Novartis Ag Biomarkers associated with BRM inhibition
AR095308A1 (es) 2013-03-15 2015-10-07 Glaxosmithkline Ip Dev Ltd Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento
US10072298B2 (en) 2013-04-17 2018-09-11 Life Technologies Corporation Gene fusions and gene variants associated with cancer
CN118910253A (zh) 2013-04-17 2024-11-08 生命技术公司 与癌症相关的基因融合体和基因变异体
JP6397897B2 (ja) 2013-05-14 2018-09-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
KR20160013028A (ko) 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 키나제 조정을 위한 화합물 및 그에 대한 적응증
EP3019489A4 (fr) 2013-07-11 2016-12-28 Betta Pharmaceuticals Co Ltd Modulateurs de la protéine tyrosine kinase et méthodes d'utilisation
JP6534930B2 (ja) 2013-07-26 2019-06-26 公益財団法人がん研究会 Ｎｔｒｋ３融合体の検出法
WO2015017533A1 (fr) 2013-07-30 2015-02-05 Blueprint Medicines Corporation Fusions de ntrk2
US10875930B2 (en) 2013-07-30 2020-12-29 Blueprint Medicines Corporation PIK3C2G fusions
JP6493681B2 (ja) 2013-08-20 2019-04-03 学校法人関西医科大学 肺がんで見出された新規融合遺伝子
EP3039021A1 (fr) 2013-08-30 2016-07-06 Ambit Biosciences Corporation Composés de biaryle acétamide et procédés d'utilisation de ceux-ci
WO2015039006A1 (fr) 2013-09-16 2015-03-19 The General Hospital Corporation Procédés de traitement du cancer
PT3409674T (pt) 2013-10-17 2022-07-18 Blueprint Medicines Corp Processo para preparar composições úteis para tratar distúrbios relacionados com kit
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
AU2014340398A1 (en) 2013-10-24 2016-06-09 Georgetown University Methods and compositions for treating cancer
BR112016008849B8 (pt) 2013-10-25 2022-09-06 Blueprint Medicines Corp Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
WO2015064621A1 (fr) 2013-10-29 2015-05-07 公益財団法人がん研究会 Nouvelles fusions, et procédé pour leur détection
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
US9801880B2 (en) 2013-12-02 2017-10-31 Bergenbio As Use of kinase inhibitors
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
HRP20191283T1 (hr) 2014-01-24 2019-10-18 Turning Point Therapeutics, Inc. Diaril makrocikli kao modulatori protein kinaze
HUE055357T2 (hu) 2014-02-05 2021-11-29 VM Oncology LLC Vegyületek kompozíciói és azok alkalmazásai
EP3738952A1 (fr) 2014-02-14 2020-11-18 Exelixis, Inc. Formes solides cristallines du n-{4-[(6,7-diméthoxyquinolin-4-yl)oxy]phényl}-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
EP3132056B1 (fr) 2014-04-18 2021-11-24 Blueprint Medicines Corporation Fusions de pik3ca
US20170044621A1 (en) 2014-04-18 2017-02-16 Blueprint Medicines Corporation Met fusions
LT3154959T (lt) 2014-05-15 2019-09-25 Array Biopharma, Inc. 1-((3s,4r)-4-(3-fluorfenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)karbamidas kaip trka kinazės inhibitorius
WO2015183836A1 (fr) 2014-05-27 2015-12-03 Brian Haynes Compositions, procédés et utilisations relatifs à des fusions ntrk2-tert
WO2015183837A1 (fr) 2014-05-27 2015-12-03 Brian Haynes Compositions, procedes, et utilisations associees a des fusions ntrk2-tert
US20170114415A1 (en) 2014-05-30 2017-04-27 The Regents Of The University Of Colorado, A Body Corporate Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
EP3155131B1 (fr) 2014-06-10 2020-02-12 Blueprint Medicines Corporation Fusions de raf1
US10246750B2 (en) 2014-06-10 2019-04-02 Blueprint Medicines Corporation Method for detection of a TECR:PKN1 or an ANXA4:PKN1 gene fusion
EP3169804B3 (fr) 2014-07-17 2019-09-18 Blueprint Medicines Corporation Fusions de fgr
US10370723B2 (en) 2014-07-17 2019-08-06 Blueprint Medicines Corporation TERT fusions
EP3169809B1 (fr) 2014-07-17 2020-04-29 Blueprint Medicines Corporation Fusions de prkc
ES2747249T3 (es) 2014-07-17 2020-03-10 Sunshine Lake Pharma Co Ltd Derivados de 1-(5-(terc-butil)isoxazol-3-il)-3-(4-((fenil)etinil)fenil)urea y compuestos relacionados como inhibidores de FLT3 para el tratamiento de cáncer
KR20170042614A (ko) 2014-08-01 2017-04-19 파마싸이클릭스 엘엘씨 Btk 저해제를 이용한 치료에 대한 dlbcl의 반응을 예측하기 위한 바이오마커
WO2016022569A1 (fr) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Composés utiles pour traiter des troubles associés à kit
BR122017020365A2 (pt) 2014-08-18 2019-09-10 Ono Pharmaceutical Co sal de adição de ácido do composto inibidor de trk
US20170283404A1 (en) 2014-09-08 2017-10-05 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
MX381233B (es) 2014-09-10 2025-03-12 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret).
RS58813B1 (sr) 2014-09-10 2019-07-31 Glaxosmithkline Ip Dev Ltd Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret)
TWI538914B (zh) 2014-10-03 2016-06-21 國立交通大學 蛋白質激酶之選擇性抑制劑、其醫藥組成物及其用途
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CA2967125C (fr) 2014-11-14 2022-10-25 Nerviano Medical Sciences S.R.L. Derives 6-amino -7-bicyclo -7-deazapurine utiles en tant qu'inhibiteurs de proteine kinase
EP3218380B1 (fr) 2014-11-16 2021-03-17 Array Biopharma, Inc. Préparation d'une forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US20170356052A1 (en) 2014-11-18 2017-12-14 Blueprint Medicines Corporation Prkacb fusions
CN107207514B (zh) 2014-12-15 2020-01-24 康联制药有限公司 稠环杂芳基化合物及其作为trk抑制剂的用途
WO2016096709A1 (fr) 2014-12-16 2016-06-23 Eudendron S.R.L. Dérivés hétérocycliques modulant l'activité de certaines protéines kinases
WO2016127074A1 (fr) 2015-02-06 2016-08-11 Blueprint Medicines Corporation Utilisation de dérivés 2-(pyridine-3-yl)-pyrimidine en tant qu'inhibiteurs de ret
KR101675984B1 (ko) 2015-02-23 2016-11-14 한양대학교 에리카산학협력단 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
CA2978628A1 (fr) 2015-03-03 2016-09-09 Caris Mpi, Inc. Profilage moleculaire du cancer
WO2016149261A1 (fr) 2015-03-16 2016-09-22 Personal Genome Diagnostics, Inc. Systèmes et procédés pour analyser l'acide nucléique
WO2016168992A1 (fr) 2015-04-21 2016-10-27 Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine Préparation et utilisation de nouveaux inhibiteurs de protéine kinase
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
WO2016196141A1 (fr) 2015-05-29 2016-12-08 Ignyta, Inc. Compositions et procédés pour traiter des patients avec des cellules mutantes rtk
PE20180329A1 (es) 2015-06-01 2018-02-13 Loxo Oncology Inc Metodos para diagnosticar y tratar el cancer
US9782400B2 (en) * 2015-06-19 2017-10-10 Macau University Of Science And Technology Oncogenic ROS1 and ALK kinase inhibitor
AU2015101722A4 (en) 2015-06-19 2016-05-19 Macau University Of Science And Technology Oncogenic ros1 and alk kinase inhibitor
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
AU2016287568B2 (en) * 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
GB201512365D0 (en) 2015-07-15 2015-08-19 King S College London Novel therapy
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
EP3120851A1 (fr) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6- (2,6-dichlorophényl) -8-methyl-2-(phénylamino) -pyrido[2,3-d]pyrimidin-7-(8h)-one pour le traitement de cancers solides
KR101766194B1 (ko) 2015-08-07 2017-08-10 한국과학기술연구원 RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
US10550124B2 (en) 2015-08-13 2020-02-04 San Diego State University Foundation Atropisomerism for increased kinase inhibitor selectivity
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
WO2017049462A1 (fr) 2015-09-22 2017-03-30 合肥中科普瑞昇生物医药科技有限公司 Nouvel inhibiteur de la kinase flt3 et ses utilisations
CN105255927B (zh) 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
EP3371171B1 (fr) 2015-11-02 2023-10-25 Blueprint Medicines Corporation Inhibiteurs de ret
US20190002988A1 (en) 2015-12-08 2019-01-03 Boehringer Ingelheim International Gmbh Method of using a ret fusion gene as a biomarker to select non small cell lung cancer (nsclc) and thyroid cancer patients for a cancer treatment
WO2017122815A1 (fr) 2016-01-15 2017-07-20 公益財団法人がん研究会 Nouveau fusant et son procédé de détection
WO2017127835A2 (fr) 2016-01-22 2017-07-27 The Medicines Company Formulations aqueuses, et procédés de préparation et d'utilisation de celles-ci
TWI620748B (zh) 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
ES2775751T3 (es) 2016-02-23 2020-07-28 Taiho Pharmaceutical Co Ltd Nuevo compuesto de pirimidina condensada o sal del mismo
WO2017145050A1 (fr) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Dérivé de pyridylpyridone utile comme inhibiteur de la kinase ret dans le traitement du sci et du cancer
WO2017155018A1 (fr) 2016-03-11 2017-09-14 小野薬品工業株式会社 AGENT THÉRAPEUTIQUE CIBLANT LES CANCERS RÉSISTANTS AUX INHIBITEURS DES Trk
WO2017161269A1 (fr) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibiteurs des tyrosine kinases du récepteur ret
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
IL304018A (en) 2016-04-04 2023-08-01 Loxo Oncology Inc Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide
IL297192A (en) 2016-04-15 2022-12-01 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
SMT202200348T1 (it) 2016-04-15 2022-11-18 Cancer Research Tech Ltd Composti eterociclici come inibitori della chinasi ret
EP3445361A1 (fr) 2016-04-19 2019-02-27 Exelixis, Inc. Procédé de traitement du cancer du sein négatif triple
WO2017197051A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles
WO2017201156A1 (fr) 2016-05-18 2017-11-23 Duke University Méthode de traitement du cancer colorectal métastatique kras sauvage au moyen de cabozantinib et de panitumumab
ES2952056T3 (es) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
WO2017207696A1 (fr) 2016-06-01 2017-12-07 F. Hoffmann-La Roche Ag Nouvelles mutations dans la réponse de prédiction de la kinase du lymphome anaplasique à une thérapie par inhibiteur d'alk chez des patients atteints du cancer du poumon
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
MX389966B (es) 2017-01-20 2025-03-20 Exelixis Inc Combinaciones de cabozantinib y atezolizumab para tratar cancer.
CN108456163A (zh) 2017-02-20 2018-08-28 中国科学院上海药物研究所 含邻氨基杂芳环炔基的化合物及其制备方法和用途
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor

Also Published As

Publication number Publication date
CN110769820A (zh) 2020-02-07
JOP20190213A1 (ar) 2019-09-16
WO2018170381A1 (fr) 2018-09-20
US20190076437A1 (en) 2019-03-14
KR20190126003A (ko) 2019-11-07
RU2019132666A (ru) 2021-04-16
IL269216A (en) 2019-11-28
US20190076436A1 (en) 2019-03-14
PH12019502069A1 (en) 2020-09-14
TW201838631A (zh) 2018-11-01
US10966985B2 (en) 2021-04-06
US20190151322A1 (en) 2019-05-23
CA3056754A1 (fr) 2018-09-20
JP2020514356A (ja) 2020-05-21
US10688100B2 (en) 2020-06-23
EP3595651A1 (fr) 2020-01-22
CL2019002612A1 (es) 2020-05-29
SG11201908532UA (en) 2019-10-30
MX2019010988A (es) 2020-02-05
BR112019019101A2 (pt) 2020-04-22
TN2019000263A1 (en) 2021-01-07
AU2018234726A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
FR24C1009I2 (fr) Composés utilisés comme inhibiteurs de kinase
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3733671A4 (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
EP3733673A4 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA46045A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA49956A (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA45669A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA44860A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
EP3706749A4 (fr) Composés macrocycliques en tant qu'inhibiteurs de kinase trk et leurs utilisations
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp